Company intelligence / Profile preview

Jounce Therapeutics

Ownership: Private
Employees: ~141
Development stage: Phase 2

Overview

As of early/mid–2023, the company’s lead program vopratelimab failed to meet its primary endpoint in a Phase II trial for non-small cell lung cancer. The macrophage-targeting antibody JTX‑8064 remained under clinical investigation with interim data pending. The company restructured and ultimately agreed to be acquired by Concentra Biosciences.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Immunotherapies
Industry: Biotech

Drug pipeline

4 assets

JTX-8064

Phase 1

Indications: Advanced solid tumors

3 more assets in the full pipeline.

Request access →

Partnerships

Gilead Sciences licensed rights to the GS–1811/JTX–1811 immuno-oncology program from Jounce Therapeutics.

Beyond the preview

Go deeper on Jounce Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jounce Therapeutics.

Explore the full profile